| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
1 Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 2 Cancer Susceptibility Unit and Genetic Epidemiology Unit, IARC, Lyon, France; and 3 Myriad Genetics Laboratories, Inc., Salt Lake City, Utah
Requests for reprints: Fergus J. Couch, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-3623; Fax: 507-266-0824; E-mail: couch.fergus{at}mayo.edu.
The influence of germ line BRCA2 unclassified variants (UCV), including missense mutations and in-frame deletions and insertions on BRCA2 function and on cancer risk, has not been defined although these mutations account for 43% of all identified BRCA2 sequence alterations. To investigate the effects of UCVs on BRCA2 function, we compared mutant and wild-type forms of BRCA2 using assays of cellular survival and viability, homologous recombination repair, and genome instability. We confirm that the effects of known deleterious mutations can be distinguished from neutral polymorphisms and wild-type BRCA2 in these assays, and we characterize the influence of a series of UCVs on BRCA2 function. We also describe how the results from the assays can be combined with data from analysis of cosegregation of the UCVs with cancer, co-occurrence of the UCVs with other deleterious mutations, and interspecies sequence variation in a comprehensive framework in an effort to better distinguish between disease predisposing and neutral UCVs. This combined approach represents a useful means of addressing the functional significance and cancer relevance of UCVs in BRCA2.
Key Words: BRCA2 • breast cancer • unclassified variant • functional assay
This article has been cited by other articles:
|
|
 |
|
  D. J. Farrugia, M. K. Agarwal, V. S. Pankratz, A. M. Deffenbaugh, D. Pruss, C. Frye, L. Wadum, K. Johnson, J. Mentlick, S. V. Tavtigian, et al. Functional Assays for Classification of BRCA2 Variants of Uncertain Significance Cancer Res., May 1, 2008; 68(9): 3523 - 3531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Spurdle, S. R. Lakhani, S. Healey, S. Parry, L. M. Da Silva, R. Brinkworth, J. L. Hopper, M. A. Brown, D. Babikyan, G. Chenevix-Trench, et al. Clinical Classification of BRCA1 and BRCA2 DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis--A Report From the kConFab Investigators J. Clin. Oncol., April 1, 2008; 26(10): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Domchek and B. L. Weber Genetic Variants of Uncertain Significance: Flies in the Ointment J. Clin. Oncol., January 1, 2008; 26(1): 16 - 17. [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Couch, O. Sinilnikova, R. A. Vierkant, V. S. Pankratz, Z. S. Fredericksen, D. Stoppa-Lyonnet, I. Coupier, D. Hughes, A. Hardouin, P. Berthet, et al. AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1416 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Agalliu, E. M. Kwon, D. Zadory, L. McIntosh, J. Thompson, J. L. Stanford, and E. A. Ostrander Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer Clin. Cancer Res., February 1, 2007; 13(3): 839 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Simard, M. Dumont, A.-M. Moisan, V. Gaborieau, H. Vezina, F. Durocher, J. Chiquette, M. Plante, D. Avard, P. Bessette, et al. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer J. Med. Genet., February 1, 2007; 44(2): 107 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P Alter, P. S Rosenberg, and L. C Brody Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2 J. Med. Genet., January 1, 2007; 44(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chenevix-Trench, S. Healey, S. Lakhani, P. Waring, M. Cummings, R. Brinkworth, A. M. Deffenbaugh, L. A. Burbidge, D. Pruss, T. Judkins, et al. Genetic and Histopathologic Evaluation of BRCA1 and BRCA2 DNA Sequence Variants of Unknown Clinical Significance Cancer Res., February 15, 2006; 66(4): 2019 - 2027. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
